GenSight Biologics S.A.: GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ Injections at 3-Year Follow-Up of REFLECT Phase III Trial

Sustained efficacy three years after injection: statistically significant visual acuity improvement from nadir Continuous benefits in bilaterally treated patients with +17 to +20 ETDRS letters

Related Keywords

United States ,Paris ,France General ,France ,Italy ,Taiwan ,United Kingdom ,Spain ,Dennis Riedl ,James Palmer ,Gensight Biologics Euronext ,Guillaume Van Renterghem ,Nancyj Newman ,Jeanene Timberlake ,Gensight Biologics ,Bernard Gilly ,Thomas Gidoin ,International Principal Investigator ,European Union ,European Medicines Agency ,Emory University School Of Medicine Atlanta ,Best Corrected Visual Acuity ,Business Wire ,Sight Biologics ,Emory University School ,Special Protocol Assessment ,Leber Hereditary Optic Neuropathy ,Sight Biologic ,Mitochondrial Targeting Sequence ,Gensight Biologic ,Hereditary Optic Neuropathy ,Institut De La Vision ,Adeno Associated Virus ,Financial Officer ,Gensight ,Iologics ,Onfirms ,Sustained ,Efficacy ,Safety ,Bilateral ,Umevoq ,Injections ,Ear ,Follow ,Reflect ,Hase ,Trial ,